Octreotide (somatostatin analog) treatment reduces endothelial cell dysfunction in patients with diabetes mellitus

Clemens, Andreas; Klevesath, M. S.; Hofmann, M.; Raulf, Friedrich; Henkels, M.; Amiral, Jean; Seibel, Markus J.; Zimmermann, Jürgen; Ziegler, Reinhard; Wahl, Peter; Nawroth, Peter P.

doi:10.1016/s0026-0495(99)90261-5

Cited by 23 publications

(13 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Octreotide, a SST analogue with high affinity for SSTR2, inhibits experimental angiogenesis (Woltering et al ., 1991;Grant et al ., 1993;Danesi & Del Tacca, 1996;Danesi et al ., 1997;Clemens et al ., 1999;Lawnicka et al ., 2000;Koizumi et al ., 2002;Spraul et al ., 2002;Jia et al ., 2003). Octreotide, a SST analogue with high affinity for SSTR2, inhibits experimental angiogenesis (Woltering et al ., 1991;Grant et al ., 1993;Danesi & Del Tacca, 1996;Danesi et al ., 1997;Clemens et al ., 1999;Lawnicka et al ., 2000;Koizumi et al ., 2002;Spraul et al ., 2002;Jia et al ., 2003).…”

mentioning

confidence: 99%

Inhibition of endothelial proliferation by the somatostatin analogue SOM230

Adams¹,

Adams²,

Lindow³

et al. 2004

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Inhibition of endothelial proliferation by the somatostatin analogue SOM230

Adams¹,

Adams²,

Lindow³

et al. 2004

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…In addition to proliferation, SRIF and SRIF analogs appear to regulate endothelial homeostasis and SRIF analogs have been shown to reverse measures of endothelial dysfunction [82,83]. Indeed, endothelial nitric oxide responses to SRIF vary among different vascular regions and species, with rat saphenous artery demonstrating an SRIF concentration-dependent increase in nitric oxide production that was unique among the tissues examined [82].…”

Section: Srif Effects On Endothelial Homeostasismentioning

confidence: 99%

“…Indeed, endothelial nitric oxide responses to SRIF vary among different vascular regions and species, with rat saphenous artery demonstrating an SRIF concentration-dependent increase in nitric oxide production that was unique among the tissues examined [82]. In patients with diabetes mellitus, the somatostatin analog octreotide reduced plasma thrombomodulin levels and urinary albumin excretion, thereby reversing endothelial damage and possibly attenuating the vascular complications of diabetes mellitus [83]. Additionally, Schiller and colleagues recently demonstrated the ability of a SRIF analog to improve endothelial cell morphology following balloon injury [63].…”

Section: Srif Effects On Endothelial Homeostasismentioning

confidence: 99%

Somatostatin: A Hormone for the Heart?

Badway

Blake²

2005

CVP

View full text Add to dashboard Cite

Somatostatin (somatotropin release inhibitory factor; SRIF) peptides are widely distributed throughout the mammalian body and act through a family of genetically distinct, guanine nucleotide regulatory protein coupled (G-protein-coupled), cell surface receptors (sst(1-5)). Compelling evidence shows that SRIF and SRIF peptidyl analogs modulate vascular function, with actions upon smooth muscle and endothelium. SRIF receptors are known to exist in the carotid endothelium, a principal target for the pro-inflammatory cascade that accompanies coronary artery disease. SRIF-14 and SRIF analogs are anti-inflammatory but the molecular mechanism involved remains unclear. Since crucial steps in the endothelial inflammation response include endothelial activation by cytokines, adhesion molecule expression and cell-monocyte interactions, peptide agents that inhibit these steps might provide a novel strategy for reducing vascular inflammation. SRIF, acting through its cognate receptors, modulates a variety of intracellular effectors that are linked to inflammation including phosphotyrosine phosphatases, the extracellular regulated protein kinase 1 and 2 (ERK1/2) cascade, adenylyl cyclase and endothelial nitric oxide synthase. Directly or indirectly, SRIF also functions to inhibit endothelial cell proliferation and induce apoptosis. A detailed understanding of SRIF actions could provide a rational basis for using SRIF ligands in controlling vascular inflammation and inhibiting cytokine signaling, critical events in atherogenesis.

show abstract

“…Accordingly, administration of octreotide or GHRA in experimental diabetes has been shown to normalize intrarenal IGF-I levels and to ameliorate early renal/glomerular enlargement and urinary albumin excretion (UAE). 21,22 Six months of octreotide treatment in type 1 diabetic subjects has been shown to reduce UAE, 23 although no clinical trials have appeared on the effects of GHRAs on diabetic nephropathy.…”

Section: Gh/igf and Microangiopathymentioning

confidence: 99%